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RASSF2 is a novel pro-apoptotic eﬀector of K-Ras that is frequently inactivated in a variety of primary tumors by promoter
methylation. Inactivation of RASSF2 enhances K-Ras-mediated transformation and overexpression of RASSF2 suppresses tumor
cell growth. In this study, we conﬁrm that RASSF2 and K-Ras form an endogenous complex, validating that RASSF2 is a bona ﬁde
K-Ras eﬀector. We adopted an RNAi approach to determine the eﬀects of inactivation of RASSF2 on the transformed phenotype
of lung cancer cells containing an oncogenic K-Ras. Loss of RASSF2 expression resulted in a more aggressive phenotype that was
characterizedbyenhancedcellproliferationandinvasion,decreasedcelladhesion,theabilitytogrowinananchorage-independent
manner and cell morphological changes. This enhanced transformed phenotype of the cells correlated with increased levels of
activated AKT, indicating that RASSF2 can modulate Ras signaling pathways. Loss of RASSF2 expression also confers resistance to
taxol and cisplatin, two frontline therapeutics for the treatment of lung cancer. Thus we have shown that inactivation of RASSF2,
a process that occurs frequently in primary tumors, enhances the transforming potential of activated K-Ras and our data suggests
that RASSF2 may be a novel candidate for epigenetic-based therapy in lung cancer.
1.Introduction
RASSF2 is a member of the RASSF family of proteins
which consists of 10 family members (RASSF1–10). While
all the family members are characterized by a conserved
RalGDS/AF6 Ras association (RA) domain either in the C-
terminal(RASSF1–6)orN-terminaloftheprotein(RASSF7–
10), only RASSF1–6 contain a conserved SARAH (Sal-
vador/RASSF/Hpo) domain adjacent to the RA domain [1–
3]. It is well established that RASSF1–6 have tumor suppres-
sor activity, and recent evidence suggests that other members
of the family may also function as tumor suppressors [1, 3–
8].
Although RASSF2 is structurally related to the better
characterized RASSF1A, the mechanisms by which these two
family members promote cell death may diﬀer as RASSF2
localizes predominantly to the nucleus [9, 10]w h e r e a s
RASSF1A is found primarily in the cytoplasm. RASSF2
binds to K-Ras in a GTP-dependent manner [11]a n dm a y
serve as a K-Ras-speciﬁc eﬀector as it forms an endogenous
complex with K-Ras [12]. RASSF2 has no apparent intrinsic
enzymatic activity or DNA binding properties and thus acts
by interacting with other proapoptotic eﬀectors and tumor
suppressors, including PAR-4 [13] and the MST1/2 kinases
[14, 15], thereby regulating the pathways these eﬀectors
control.
Like RASSF1A, RASSF2 is inactivated in a variety of
tumors by promoter methylation [8, 9, 11, 13, 16–23].
RASSF2 has the properties of a tumor suppressor in that its
overexpression promotes apoptosis and cell cycle arrest in
vitro and inhibits tumor cell growth and tumor xenograft
formation in nude mice [9, 11]. Conversely, loss of RASSF2
expression results in enhanced growth in soft agar and
transformation [24]. Loss of RASSF2 may also promote
metastasis [23, 25]. RASSF2 may function in additional
biological processes other than apoptosis and growth sup-
pression as suggested by RASSF2 knockout mice. These mice
develop normally for the ﬁrst two weeks after birth, where
after they develop growth retardation and die approximately
4 weeks after birth [26]. Additionally, these mice develop2 Molecular Biology International
systemic lymphopenia and altered bone development. This
suggests that RASSF2 has important functions in early post-
natal development and further conﬁrms that RASSF2 has
functions distinct from RASSF1A as RASSF1A knockout
mice develop normally [27, 28].
Although RASSF2 is expressed in a wide variety of tissues
[26], its expression is somewhat tissue speciﬁc, with the
highest levels detected in brain, peripheral blood, and lung
[11]. RASSF2 is frequently downregulated in lung cancer
[9, 11, 19] with inactivation of RASSF2 being more prevalent
in NSCLC than SCLC. K-Ras is frequently mutated in
lung cancer [29], and inactivation of RASSF2 enhances the
transforming potential of K-Ras in rat kidney cells [24].
Several reports indicate that there is a positive correlation
between K-Ras/BRAF mutations and RASSF2 methylation
in primary tumors [21, 24, 30]. Thus, inactivation of
RASSF2 confers a growth advantage to tumor cells harboring
activated K-Ras, and loss of RASSF2 expression may be a key
event in Ras-mediated transformation.
To date, the majority of studies examining the eﬀects of
RASSF2 on the transformed phenotype rely on overexpres-
sion assays, which although providing useful information,
have some drawbacks in that overexpression of proteins
from viral promoters may yield expression levels far above
physiological levels, thereby generating data that may not
be physiologically relevant. We have used RNAi technology
to reduce RASSF2 expression levels, a situation that more
accurately mimics what occurs in primary tumors, to
determinetheroleofRASSF2inactivationintransformation.
Loss of RASSF2 expression in lung cancer cells dramatically
enhanced the transformed phenotype, decreased cell adhe-
sion, and increased invasion. These eﬀects were associated
with elevated levels of activated AKT. Furthermore, inacti-
vation of RASSF2 conferred resistance to taxol and cisplatin,
suggesting that RASSF2 may be a target for epigenetic
therapy in lung cancer.
2.MaterialsandMethods
2.1.CellLinesandCultureConditions. H441lungcancercells
were maintained in RPMI1640 (Mediatech Inc., Herndon,
VA) supplemented with 10% fetal bovine serum (FBS;
Mediatech Inc.) and 1% penicillin-streptomycin (Mediatech
Inc.).
2.2.KnockdownofRASSF2byShortHairpinRNA. H441cells
were transfected with pLKO.1 lentiviral constructs encoding
shRNA molecules to RASSF2 with the following sequences:
shF2 number 1, 5 -TCTGAAGACCTACAACTTGTA-3  and
shF2 number 2, 5-GCCACCGATTACCCGCTGATT-3 ,a n d
a control shRNA that corresponded to RASSF2 sequences
but which was ineﬀective at reducing RASSF2 levels
5 -CCTCCCAAGTAGCTGGAATTA-3  (Open Biosystems,
Lafayette, CO) using Lipofectamine 2000 (Invitrogen, Carls-
bad,CA)andselectedwithpuromycintoobtainastablebulk
population of cells.
2.3. Western Blot Analysis. T o t a lc e l ll y s a t e sw e r ep r e p a r e db y
lysing the cells in RIPA buﬀer (Sigma, St. Louis, MO) sup-
plemented with 100μg/mL leupeptin, 100μg/mL aprotinin,
and 1mM sodium orthovanadate. The lysates were passed
through a 21-gauge needle, centrifuged to remove debris,
and quantitated using the BioRad Protein Assay (BioRad,
Hercules, CA). Equal amounts of protein were resolved
on 4–12% NuPage Novex polyacrylamide gels (Invitrogen)
and incubated with antibodies against RASSF2 [11], β-
Actin (Sigma), phospho-AKT (9271), and AKT (9272) (Cell
Signaling Technology, Inc., Danvers, MA). The signal was
detected by enhanced chemiluminescence.
2.4.Immunoprecipitation. Endogenouscoimmunoprecipita-
tions of Ras and RASSF2 were performed using a Pan-
ras antibody conjugated to sepharose beads (Santa Cruz
Biotechnology Inc., Santa Cruz, CA) to immunoprecipitate
the lysate. The immunoprecipitates were then analyzed by
Western Blot using our RASSF2 antibody [11].
2.5. Cell Proliferation Assays. 2 × 105 cells per well were
plated in 6-well plates and incubated for 6 days. Cell number
was determined each day by counting the number of viable
cells in one well of each plate for the diﬀerent cell lines.
Experiments were performed twice in duplicate.
2.6. Cytotoxicity Assays. 5 × 104 cells per well were plated
in 12-well plates and incubated with 5nM taxol, 50μM
cisplatin, or vehicle for 3 days. The number of surviving
cells was determined by cell counting. Experiments were
performed twice in duplicate.
2.7. Soft Agar Assays. 1 × 104 cells were plated in 6mL of
0.35% agar in complete growth medium overlaid on a 0.7%
agar base, also in complete growth medium. The cells were
incubated at 37◦C for 2 weeks and resulting colonies were
counted after staining for 16hr with p-iodonitrotetrazolium
violet. Experiments were performed twice in duplicate.
2.8. Adhesion Assays. Cell adhesion assays were performed
essentially as described [31]. Brieﬂy, 5 × 104 cells per well
were plated in BSA-coated 96-well plates and allowed to
adhere for 45min at 37◦C. The medium was removed and
the adhering cells ﬁxed and stained with crystal violet. The
dye was solubilized, and absorbance at 570nm was used as a
measure of adhesion.
2.9. Invasion Assays. 1 × 105 cells per well were plated on
a collagen plug in serum-free growth medium in transwell
inserts. The inserts were placed in 12-well plates containing
complete growth medium and incubated at 37◦Cf o r7d a y s .
Cells on the inner surface of the transwell membrane were
removed by scraping with a cotton swab, and cells remaining
on the outer surface of the membrane were ﬁxed and
stained with crystal violet. The number of cells remaining
on the outer surface of the transwell membrane was then
quantitated by cell counting.Molecular Biology International 3
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Figure 1:RASSF2andK-Rasformanendogenouscomplex.Lysates
from H441 and H1299 lung cancer cells were immunoprecipi-
tated with a pan Ras antibody, fractionated on SDS gels, and
immunoblotted with an anti-RASSF2 antibody. The endogenous
interactionbetweenRasandRASSF2wasconﬁrmedbythepresence
of RASSF2 in the proteins precipitated from the H441 cells but not
the RASSF2-negative H1299 cells.
3. Results
3.1. RASSF2 Forms an Endogenous Complex with K-Ras.
RASSF2 has previously been shown to directly bind to K-
Ras in vitro in a GTP-dependent manner [11]. To conﬁrm
that RASSF2 and K-Ras can form an endogenous complex,
we serum-starved then brieﬂy serum-stimulated H441 lung
cancer cells that express mutant K-Ras and retain RASSF2
expression [11]. The cells were then lysed and immunopre-
cipitated with a pan-Ras antibody conjugated to sepharose
beads and the immunoprecipitate subjected to Western Blot-
ting with a RASSF2 antibody [11]( Figure 1). The presence
of RASSF2 in the immunoprecipitate conﬁrmed that the
interaction between RASSF2 and K-Ras is physiologically
relevant and RASSF2 is a bone ﬁde Ras eﬀector.
3.2. Downregulation of RASSF2 Enhances the Proliferation of
Tumor Cells. To determine the biological eﬀects of downreg-
ulating RASSF2, we used two independent RASSF2 shRNA
constructs to generate stable RASSF2 knockdown cell lines
in H441 lung cancer cells. An shRNA molecule that did
not knockdown RASSF2 was used as a control. Knockdown
of RASSF2 expression in the H441 cells was validated by
Western Blotting using our RASSF2 antibody (Figure 2(a)).
Analysis of cell proliferation conﬁrmed that the RASSF2
knockdown cells exhibited statistically signiﬁcant (P<
0.05) enhanced proliferation compared to control cells
(Figure 2(b)).
3.3. Loss of RASSF2 Expression Promotes the Transformed
Phenotype. To determine the eﬀects of loss of RASSF2
expression on the transformed phenotype, we plated the
H441 RASSF2 knockdown cells in soft agar and compared
their ability to form colonies with that of the control
cells (Figure 2(c)) .T h ep l a t e sw e r ee x a m i n e d2w e e k sa f t e r
plating and scored for the number of colonies. The cells in
which RASSF2 had been knocked down formed signiﬁcantly
more colonies than the control cells (P<0.05) and the
colonies that formed were also much larger (Figure 2(c)).
These results are consistent with previous reports showing
that inactivation of RASSF2 enhances K-Ras-induced cell
transformation [24].
3.4. Inactivation of RASSF2 Results in a More Aggressive
Phenotype. Overexpression of RASSF2 has been shown
to induce cell morphological changes [24], and we have
conﬁrmed this in our RASSF2 knockdown cells. Loss of
RASSF2 expression resulted in a dramatic alteration in
cell morphology. The control H441 cells had a ﬂattened
morphology and grew in a monolayer, whereas the cells
stably expressing the RASSF2 shRNA constructs became
more rounded, piled up on each other, and were more
refractile, consistent with a more aggressive and transformed
phenotype (Figure 3).
The RASSF2 knockdown cells also exhibited a signiﬁcant
decrease in the degree of adhesion compared to the control
cells (Figure 4(a)), a characteristic frequently associated with
transformed cells that correlates with enhanced motility. In
addition,lossofRASSF2expressionenhancedinvasionofthe
cells. Signiﬁcantly more cells stably expressing the RASSF2
shRNA constructs were able to invade through a collagen
matrix compared to control cells (Figure 4(b)). This result
is in agreement with other published reports showing that
over expression of RASSF2 inhibits migration [23]. Taken
together, these data suggests that loss of RASSF2 expression
confers a more aggressive phenotype to lung cancer cells.
3.5. Loss of RASSF2 Expression Activates Growth Promoting
Pathways. Since loss of RASSF2 expression resulted in
enhancedgrowthandtransformation,wereasonedthatinac-
tivation of RASSF2 activated growth promoting pathways.
In an eﬀort to determine which prosurvival pathways were
activated in the H441 cells knocked down for RASSF2,
we analyzed the phosphorylation status of AKT in these
cells. Western Blot analysis showed that levels of phospho-
rylated AKT increased in the cells stably expressing the
RASSF2shRNAconstructsrelativetocontrolcells(Figure 5).
Previous studies have found an association between the
methylation status of RASSF2 and the levels of activated
AKT. Oral squamous cell carcinomas in which RASSF2 is
methylated showed higher levels of activated AKT [18].
Taken together, our results and those from previous reports
suggestthatlossofRASSF2expressionresultsinactivationof
growth promoting pathways.
3.6. Loss of RASSF2 Expression Confers Resistance to Chem-
otherapeutic Agents. To determine whether the more aggres-
sive phenotype of the RASSF2 knockdown cells altered their
response to chemotherapeutic agents, we treated the cells
with taxol or cisplatin, two drugs commonly used in the
treatment of nonsmall cell lung cancer, and measured their
eﬀects on cell death. Both taxol and cisplatin resulted in
increasedcelldeathinthecontrolcellsbyapproximately40%
and 50%, respectively. However, in the cells stably knocked
down for RASSF2, taxol had no eﬀect on cell growth and
the cisplatin-induced cell death was somewhat abrogated
(Figure 6). Thus, loss of RASSF2 expression confers resis-
tance to taxol and cisplatin.4 Molecular Biology International
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Figure 2: Loss of RASSF2 enhances proliferation and tumorigenicity of lung cancer cells. H441 lung cancer cells were transfected with two
independent RASSF2 shRNA constructs and a noneﬀective shRNA and selected in puromycin for 2 weeks to obtain a population of cells
stablyexpressingthevariousshRNAconstructs.KnockdownofRASSF2expressionwasconﬁrmedbyWesternBlotting(a).Actinwasusedas
acontrolforproteinloading.(b)GrowthanalysisoftheH441shF2cells.Cellswereharvestedandcountedattheindicatedtimestodetermine
cell number. P<0.05 for both shF2-transfected cells compared to control cells. (c) H441 cells stably expressing the shRNA constructs to
RASSF2 or control shRNA were plated in soft agar and colony number determined after 14 days. ∗Statistically diﬀerent (P<0.05) from cells
expressing the control shRNA. The panel on the right shows representative images of the colonies.
4. Discussion
RASSF2 is a novel K-Ras-speciﬁc eﬀector that negatively
regulates Ras signaling. It has the properties of a tumor
suppressor with eﬀects on apoptosis, cell cycle, and cell
migration [9, 11, 23, 24]. It may play an important role in
tumorigenesis as its expression is silenced in many tumor
types by promoter methylation [4, 6, 8, 11–14, 17–19].
Moreover, inactivation of RASSF2 may be an early event in
tumorigenesis as it is found inactivated in a high proportion
of colon adenomas as well as early stages of prostate cancer
[13, 17, 24], raising the possibility that loss of function of
RASSF2 may be an initiating event in the development of
certain tumor types.
To determine the eﬀects of inactivation of RASSF2 on the
transformed phenotype, we established a cell line in whichMolecular Biology International 5
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Figure 3: Inactivation of RASSF2 causes morphology changes. H441 cells stably expressing RASSF2 shRNA constructs and a control shRNA
were viewed and photographed using phase contrast at 100x magniﬁcation.
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Figure 4: Loss of RASSF2 decreases cell adhesion and enhances invasion. (a) The H441 control cells and those stably knocked down for
RASSF2 were assayed for adhesion as described in Section 2. ∗Statistically diﬀerent (P<0.05) from control cells. (b) The cells were assayed
for their ability to invade a collagen matrix as described in Section 2. A statistically larger number of cells (P<0.05) that were stably knocked
down for RASSF2 were able to migrate through the collagen compared to control cells, indicating that loss of RASSF2 enhances cell invasion.6 Molecular Biology International
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pathways. Lysates from the control H441 cells and those stably
transfected with the RASSF2 shRNA constructs were prepared,
fractionated on SDS gels, and immunoblotted with antibodies
against phosphorylated or total AKT. Loss of RASSF2 expression
increased the levels of phosphorylated AKT.
0
20
40
60
80
100
120
140
S
u
r
v
i
v
a
l
 
(
%
)
∗∗ ∗∗
Vehicle
5nM taxol
10µM cisplatin
Control shF2 number 1 shF2 number 2
Figure 6: Inactivation of RASSF2 confers resistance to cisplatin
and taxol. H441 cells stably transfected with control and RASSF2
shRNA constructs were seeded at 2 × 104 cells per well in 12-
well plates and treated with 5nM taxol or 10μM cisplatin for 3
days. Cell death was estimated by trypan blue exclusion. Cells stably
transfected with the RASSF2 shRNA showed signiﬁcantly less cell
death (P<0.05) compared to the control cells for both taxol and
cisplatin treatments.
we stably knocked down RASSF2 expression with RNAi
technology. The cells in which RASSF2 had been inactivated
adopted a more aggressive phenotype as evidenced by their
enhanced growth in traditional 2-dimensional culture as
well as their ability to grow in an anchorage independent
manner. Consistent with this more transformed phenotype,
the RASSF2 knockdown cells were less adherent than control
cells, had an altered morphology, and showed an increased
invasive potential. These results conﬁrm and support previ-
ous studies showing that overexpression of RASSF2 inhibits
growth, migration, and transformation [9, 11, 18, 23, 24].
The molecular mechanisms by which RASSF2 inhibits
growth are not fully understood. Since RASSF2 has no
inherent enzymatic activity or DNA binding properties, it
more than likely acts by interacting with other proapoptotic
eﬀectors thereby modulating growth inhibitory pathways,
much like the better characterized RASSF1A [1, 3]. We have
previously shown that RASSF2 forms a direct and physiolog-
ically relevant complex with the proapoptotic eﬀector PAR-
4[ 13], thereby modulating PAR-4 function. Other reports
have shown that RASSF2 interacts with the Mst1/2 kinases,
thereby regulating the Hippo signaling pathway [14, 15].
Thus, RASSF2 may act as a scaﬀold integrating multiple
tumor suppressor pathways.
There is now conclusive evidence to support RASSF2
as a K-Ras-speciﬁc eﬀector. RASSF2 binds to K-Ras in
a GTP-dependent manner [11], and our data shows that
RASSF2 and K-Ras form an endogenous complex (Figure 1).
Furthermore, RASSF2 and K-Ras have been shown to
interact at physiologically relevant levels in primary tissue
[12]. Moreover, H441 lung cancer cells harbor a mutant K-
Ras,andlossofRASSF2expressioninthesecellsdramatically
enhanced their transformed phenotype. This data supports
a previous study showing that inactivation of RASSF2
enhances K-Ras-mediated cell transformation in rat kidney
cells [24]. It is now becoming clear that oncogenic K-Ras
can both promote cellular proliferation as well as stimulate
apoptosis [32]. Thus, RASSF2 may serve to keep the growth
promoting activity of oncogenic K-Ras in check and loss of
RASSF2 expression may then allow the growth promoting
eﬀects of activated K-Ras to dominate and override its
growth suppressive eﬀects.
In an eﬀort to determine the mechanism behind the
aggressive phenotype of the H441 cells in which RASSF2
levels were decreased, we examined the activation status of
Ras-controlled signaling pathways and found an increase
in activated AKT (Figure 5). This result is consistent with
previous studies showing that cell lines in which the RASSF2
promoter is methylated had higher levels of activated AKT
compared to those cell lines in which the RASSF2 promoter
was not methylated [18]. Interestingly, no eﬀect on MAPK
signaling molecules was observed in cells from RASSF2
knockout mice during osteoblast diﬀerentiation [26]. Thus,
it appears that the eﬀects of RASSF2 in modulating Ras-
mediated signaling pathways may be somewhat speciﬁc.
Since RASSF2 can interact directly with activated K-Ras, it
remainstobedeterminedexactlyhowRASSF2canselectively
regulatesome Ras-mediated signaling pathwayswhilehaving
little eﬀect on others. RASSF2 interacts preferentially with K-
Ras [11] and may thus negatively impact K-Ras-speciﬁc sig-
nalingpathwayswithoutimpactingthosepathwaysmediated
byH-RasorN-Ras.ItispossiblethatRASSF2mayhavesome
direct eﬀects on the regulation of AKT activity, but further
studies are required to determine whether this is indeed the
case.
One possible explanation for the increased growth and
transformed phenotype of the RASSF2 knockdown cells
is enhanced NF-κB signaling which may be promoted
by inactivation of RASSF2. RASSF2 can modulate NF-κB
signalingbymultiplemechanisms.Firstly,itformsacomplexMolecular Biology International 7
with IκBα and β [26], thereby directly regulating the NF-
κB signaling pathway. Secondly, loss of RASSF2 is associated
with elevated levels of activated AKT (Figure 5 and [18]),
which can then activate NF-κB signaling. AKT promotes
tumor cell invasion which can occur via NF-κB signaling
[33–36]. Thirdly, inactivation of PAR-4 results in aberrant
NF-κB signaling [37], and we have shown that RASSF2
is required for the full apoptotic eﬀects of PAR-4 [13].
Thus, RASSF2 may regulate NF-κB signaling both directly
and indirectly, and loss of RASSF2 expression results in
deregulated NF-κB signaling that may be associated with
enhanced growth and invasion.
Our data also suggest that loss of RASSF2 expression
confersresistancetotaxolandcisplatin(Figure 6),2frontline
therapeutics for the treatment of NSCLC [38]. These two
agents oﬀer only a modest improvement in median survival
time for patients with advanced NSCLC [38]. Since RASSF2
is inactivated at a high frequency in lung cancer [9, 11, 19]
and loss of RASSF2 expression is associated with an increase
in activated AKT (Figure 5 and [18] ,at a r g e t e dt h e r a p e u t i c
approach using agents against AKT, perhaps in combination
with cytotoxic therapy, may prove more successful in at
least a subset of lung cancer patients. Currently, there are
a number of AKT inhibitors available, some of which are
already in clinical trials [39].
In summary, we found that loss of RASSF2 expression
enhances the transformed phenotype of lung cancer cells
expressingoncogenicK-Ras.Thismoreaggressivephenotype
is associated with an increase in activated AKT, suggesting
that RASSF2 can negatively regulate Ras-controlled growth
promoting pathways. Inactivation of RASSF2 also confers
resistance to cisplatin and taxol, suggesting that RASSF2, or
the signaling pathways that it regulates, may serve as a target
for therapy for lung cancer.
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